 ACE2-FC is a novel drug candidate to block coronavirus infection. It has been engineered to contain single GLC and AC residues on its surface, which increases its affinity for the RBD of SARS-CoV-2. This allows it to bind more strongly to the virus, thereby preventing it from entering host cells. In addition, this modified version of ACE2-FC displays higher virus neutralizing activity than unmodified ACE2-FC, making it a promising drug candidate to combat coronavirus infections. This article was authored by Shiva Izzati, Ulrika Vavra, Stanislav Melnik, and others.